Myeloid's unique approach involves using mRNA and protein biology to program immune cells. The company's lead programs engineer myeloid cells to activate anti-tumor immunity, utilizing chimeric antigen receptors (CAR) generated by fusing a tumor recognition scFv with the alpha chain of human Fc receptors.

This approach allows for the activation of myeloid cells within the tumor setting, leading to broad systemic anti-tumor responses. Additionally, Myeloid's technology includes autologous mRNA-engineered chimeric antigen receptor monocytes for targeted cancer immunotherapy.

Their innovative methods have shown promise in overcoming challenges related to targeting and activating myeloid cells in vivo, ultimately aiming to drive meaningful clinical outcomes for patients with cancer.

$73M - May 2023

• ARCH Venture Partners
• Hatteras
• Newpath Partners
• 8VC
• Alexandria Venture Investments 

Total: USD ~$120M Raised

• MT-302 Phase 1/2 study - Designed to seamlessly expand globally.
• MT-303 Phase 1 study. Presently in the IND-Enabling stage
  
  

Cell therapies

Oncology